Targeting the transposase domain of the DNA repair component metnase to enhance chemotherapy

Cancer Research

Volumn 72, Issue 23, 2012, Pages 6200-6208

  Williamson, Elizabeth A ^a   Damiani, Leah ^a   Leitao, Andrei ^b   Hu, Chelin ^c   Hathaway, Helen ^c   Oprea, Tudor ^c   Sklar, Larry ^c   Shaheen, Montaser ^c   Bauman, Julie ^c   Wang, Wei ^c   Nickoloff, Jac A ^d   Lee, Suk Hee ^e   Hromas, Robert ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSITY OF NEW MEXICO   (United States)

^d Department of Environmental and Radiological Health Sciences   (United States)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; CISPLATIN; DNA; ELVITEGRAVIR; FLUOROURACIL; METNASE; RALTEGRAVIR; TRANSPOSASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL STRAIN HEK293; COLON CANCER; CONTROLLED STUDY; DNA CLEAVAGE; DNA DAMAGE; DNA REPAIR; DRUG POTENTIATION; DRUG SCREENING; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME CONFORMATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; LUNG CANCER; MOLECULAR DOCKING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; TUMOR XENOGRAFT; VIRTUAL REALITY;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CIPROFLOXACIN; CISPLATIN; DNA DAMAGE; DNA REPAIR; DNA-BINDING PROTEINS; DRUG SYNERGISM; HEK293 CELLS; HISTONE-LYSINE N-METHYLTRANSFERASE; HIV INTEGRASE INHIBITORS; HUMANS; LUNG NEOPLASMS; MICE; MICE, SCID; MODELS, MOLECULAR; PROTEIN STRUCTURE, TERTIARY; TRANSPOSASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84870314994     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-0313     Document Type: Article

References (50)

1. Cordaux R, Udit S, Batzer MA, Feschotte C. Birth of a chimeric primate gene by capture of the transposase gene from a mobile element. Proc Natl Acad Sci U S A 2006;103:8101-6. (Pubitemid 43801059)
2. Jordan IK. Evolutionary tinkering with transposable elements. Proc Natl Acad Sci U S A 2006;103:7941-2. (Pubitemid 43801032)
3. Lee SH, Oshige M, Durant ST, Rasila KK, Williamson EA, Ramsey H, et al. The SET domain protein Metnase mediates foreign DNA integration and links integration to nonhomologous end-joining repair. Proc Natl Acad Sci U S A 2005;102:18075-80. (Pubitemid 41798504)
4. Robertson HM, Zumpano KL. Molecular evolution of an ancient mariner transposon, Hsmar1, in the human genome. Gene 1997;205:203-17. (Pubitemid 28029615)
5. Liu D, Bischerour J, Siddique A, Buisine N, Bigot Y, Chalmers R. The human SETMAR protein preserves most of the activities of the ancestral Hsmar1 transposase. Mol Cell Biol 2007;27:1125-32. (Pubitemid 46174572)
6. Beck BD, Lee SS, Hromas R, Lee SH. Regulation of Metnase's TIR binding activity by its binding partner, Pso4. Arch Biochem Biophys 2010;498:89-94.
7. Roman Y, Oshige M, Lee Y-J, Goodwin K, Georgiadis MM, Hromas RA, et al. Biochemical characterization of a SET and transposase fusion protein, Metnase (SETMAR) for its DNA binding and DNA cleavage activity. Biochemistry 2007;46:11369-76. (Pubitemid 47556764)
8. Fnu S, Williamson EA, De Haro LP, Brenneman M, Wray J, Shaheen M, et al. Methylation of histone H3 lysine 36 enhances DNA repair by nonhomologous end-joining. Proc Natl Acad Sci U S A 2011;108:540-5.
9. Wray J, Williamson EA, Farrington J, Chester S, Kwan L, Weinstock D, et al. The transposase domain protein Metnase/SETMAR suppresses chromosomal translocations. Cancer Genet Cytogenet 2010;200:184-90.
10. De Haro LP, Wray J, Williamson EA, Durant ST, Corwin L, Gentry AC, et al. Metnase promotes restart and repair of stalled and collapsed replication forks. Nucleic Acids Res 2010;38:5681-91.
11. Williamson EA, Rasila KK, Corwin LK, Wray J, Beck BD, Severns V, et al. The SET and transposase domain protein Metnase enhances chromosome decatenation: regulation by automethylation. Nucleic Acids Res 2008;36:5822-31.
12. Wray J, Williamson EA, Fnu S, Lee S-H, Libby E, Willman CL, et al. Metnase mediates chromosome decatenation in acute leukemia cells. Blood 2009;114:1852-8.
13. Wray J, Williamson EA, Royce M, Shaheen M, Beck BD, Lee SH, et al. Metnase mediates resistance to topoisomerase II inhibitors in breast cancer cells. PLoS ONE 2009;4:e5323.
14. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al. Initial sequencing and analysis of the human genome. Nature 2001;409:860-921.
15. Hawtin RE, Stockett DE, Byl JA, McDowell RS, Nguyen T, Arkin MR, et al. Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II. PLoS ONE 2010;5:e10186.
16. Beck BD, Lee SS, Williamson E, Hromas RA, Lee SH. Biochemical characterization of Metnase's endonuclease activity and its role in NHEJ repair. Biochemistry 2011;50:4360-70.
17. Leitao A, Andricopulo AD, Montanari CA. In silico screening of HIV-1 non-nucleoside reverse transcriptase and protease inhibitors. Eur J Med Chem 2008;43:1412-22. (Pubitemid 351885210)
18. Goodwin KD, He H, Imasaki T, Lee SH, Georgiadis MM. Crystal structure of the human Hsmar1-derived transposase domain in the DNA repair enzyme Metnase. Biochemistry 2010;49:5705-13.
19. Hromas R, Wray J, Lee SH, Martinez L, Farrington J, Corwin LK, et al. The human set and transposase domain protein Metnase interacts with DNA ligase IV and enhances the efficiency and accuracy of non-homologous end-joining. DNA Repair 2008;7:1927-37.
20. Chiu TK, Davies DR. Structure and function of HIV-1 integrase. Curr Top Med Chem 2004;4:965-77.
21. Savarino A. In-Silico docking of HIV-1 integrase inhibitors reveals a novel drug type acting on an enzyme/DNA reaction intermediate. Retrovirology 2007;4:21.
22. Hare S, Gupta SS, Valkov E, Engelman A, Cherepanov P. Retroviral intasome assembly and inhibition of DNA strand transfer. Nature 2010;464:232-7.
23. Drusano GL, Standiford HC, Plaisance K, Forrest A, Leslie J, Caldwell J. Absolute oral bioavailability of ciprofloxacin. Antimicrob Agents Chemother 1986;30:444-6. (Pubitemid 16017326)
24. Downey M, Durocher D. γH2AX as a checkpoint maintenance signal. Cell Cycle 2006;5:1376-81.
25. Keogh MC, Kim JA, Downey M, Fillingham J, Chowdhury D, Harrison JC, et al. A phosphatase complex that dephosphorylates γH2AX regulates DNA damage checkpoint recovery. Nature 2006;439:497-501. (Pubitemid 43152843)
26. Hardman WE, Moyer MP, Cameron IL. Efficacy of treatment of colon, lung and breast human carcinoma xenografts with: doxorubicin, cisplatin, irinotecan or topotecan. Anticancer Res 1999;19:2269-74. (Pubitemid 29392533)
27. Shoemaker AR, Oleksijew A, Bauch J, Belli BA, Borre T, Bruncko M, et al. A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo. Cancer Res 2006;66:8731-9. (Pubitemid 44449190)
28. Fan T, Li R, Todd NW, Qiu Q, Fang HB, Wang H, et al. Up-regulation of 14-3-3zeta in lung cancer and its implication as prognostic and therapeutic target. Cancer Res 2007;67:7901-6. (Pubitemid 47281386)
29. Shen H, Hu D, Du J, Wang X, Liu Y, Wang Y, et al. Paclitaxel-octreotide conjugates in tumor growth inhibition of A549 human non-small cell lung cancer xenografted into nude mice. Eur J Pharmacol 2008;601:23-9.
30. Cai KX, Tse LY, Leung C, Tam PK, Xu R, Sham MH. Suppression of lung tumor growth and metastasis in mice by adeno-associated virus-mediated expression of vasostatin. Clin Cancer Res 2008;14:939-49. (Pubitemid 351232942)
31. Sorgel F, Naber KG, Kinzig M, Mahr G, Muth P. Comparative pharmacokinetics of ciprofloxacin and temafloxacin in humans: a review. Am J Med 1991;91:51S-66S.
32. Cocohoba J, Dong BJ. Raltegravir: the first HIV integrase inhibitor. Clin Ther 2008;30:1747-65.
33. Somekh E, Douer D, Shaked N, Rubinstein E. In vitro effects of ciprofloxacin and pefloxacin on growth of normal human hematopoietic progenitor cells and on leukemic cell lines. J Pharmacol Exp Ther 1989;248:415-8. (Pubitemid 19063521)
34. Seay TM, Peretsman SJ, Dixon PS. Inhibition of human transitional cell carcinoma in vitro proliferation by fluoroquinolone antibiotics. J Urol 1996;155:757-62. (Pubitemid 26023598)
35. Miclau T, Edin ML, Lester GE, Lindsey RW, Dahners LE. Effect of ciprofloxacin on the proliferation of osteoblast-like MG-63 human osteosarcoma cells in vitro. J Orthop Res 1998;16:509-12. (Pubitemid 28427703)
36. Herold C, Ocker M, Ganslmayer M, Gerauer H, Hahn EG, Schuppan D. Ciprofloxacin induces apoptosis and inhibits proliferation of human colorectal carcinoma cells. Br J Cancer 2002;86:443-8. (Pubitemid 34185131)
37. Scatena CD, Kumer JL, Arbitrario JP, Howlett AR, Hawtin RE, Fox JA, et al. Voreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivo. Cancer Chemother Pharmacol 2010;66:881-8.
38. Kloskowski T, Gurtowska N, Nowak M, Joachimiak R, Bajek A, Olkowska J, et al. The influence of ciprofloxacin on viability of A549, HepG2, A375.S2, B16 and C6 cell lines in vitro. Acta Pol Pharm 2011;68:859-65.
39. Walsby EJ, Coles SJ, Knapper S, Burnett AK. The topoisomerase II inhibitor voreloxin causes cell cycle arrest and apoptosis in myeloid leukemia cells and acts in synergy with cytarabine. Haematologica 2011;96:393-9.
40. Wei H, Ruthenburg AJ, Bechis SK, Verdine GL. Nucleotide-dependent domain movement in the ATPase domain of a human type IIA DNA topoisomerase. J Biol Chem 2005;280:37041-7. (Pubitemid 41587788)
41. Drlica K, Malik M, Kerns RJ, Zhao X. Quinolone-mediated bacterial death. Antimicrob Agents Chemother 2008;52:385-92. (Pubitemid 351170804)
42. Aranha O, Grignon R, Fernandes N, McDonnell TJ, Wood DP Jr, Sarkar FH. Suppression of human prostate cancer cell growth by ciprofloxacin is associated with cell cycle arrest and apoptosis. Int J Oncol 2003;22:787-94.
43. Koziel R, Szczepanowska J, Magalska A, Piwocka K, Duszynski J, Zablocki K. Ciprofloxacin inhibits proliferation and promotes generation of aneuploidy in Jurkat cells. J Physiol Pharmacol 2010;61:233-9.
44. Mills DA, Fekrazad HM, Verschraegen CF. SNS-595, a naphthyridine cell cycle inhibitor and stimulator of apoptosis for the treatment of cancers. Curr Opin Investig Drugs 2008;9:647-57. (Pubitemid 351777168)
45. Krug LM, Crawford J, Ettinger DS, Shapiro GI, Spigel D, Reiman T, et al. Phase II multicenter trial of voreloxin as second-line therapy in chemotherapy-sensitive or refractory small cell lung cancer. J Thorac Oncol 2011;6:384-6.
46. Wang SW, Pan SL, Huang YC, Guh JH, Chiang PC, Huang DY, et al. CHM-1, a novel synthetic quinolone with potent and selective antimitotic antitumor activity against human hepatocellular carcinoma in vitro and in vivo. Mol Cancer Ther 2008;7:350-60.
47. Hsu SC, Yang JS, Kuo CL, Lo C, Lin JP, Hsia TC, et al. Novel quinolone CHM-1 induces apoptosis and inhibits metastasis in a human osterogenic sarcoma cell line. J Orthop Res 2009;27:1637-44.
48. Chen HY, Lu HF, Yang JS, Kuo SC, Lo C, Yang MD, et al. The novel quinolone CHM-1 induces DNA damage and inhibits DNA repair gene expressions in a human osterogenic sarcoma cell line. Anticancer Res 2010;30:4187-92.
49. Engels EA, Lau J, Barza M. Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol 1998; 16:1179-87. (Pubitemid 28108756)
50. Paul M, Gafter-Gvili A, Fraser A, Leibovici L. The anti-cancer effects of quinolone antibiotics? Eur J Clin Microbiol Infect Dis 2007;26:825-31. (Pubitemid 47573386)